Jorg Taubel

St. George's University Of London
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

Journal: The New England journal of medicine

Published: May 26, 2026

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

Journal: The New England journal of medicine

Published: September 26, 2025

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.

Journal: The British journal of dermatology

Published: March 12, 2025

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.

Journal: The New England journal of medicine

Published: November 18, 2024

Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy.

Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy.

Journal: Circulation. Heart failure

Published: October 28, 2024

Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis.

Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis.

Journal: Journal of hepatology

Published: October 21, 2024

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

Journal: The New England journal of medicine

Published: August 30, 2024

C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.

C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.

Journal: Frontiers in molecular neuroscience

Published: April 02, 2024

Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials.

Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials.

Journal: Cureus

Published: August 27, 2023

Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231).

Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231).

Journal: European journal of heart failure

Published: August 07, 2023

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.

Journal: The New England journal of medicine

Published: July 19, 2023

The Reliability of Auto-Injectors in Clinical Use: A Systematic Review.

The Reliability of Auto-Injectors in Clinical Use: A Systematic Review.

Journal: Cureus

Published: July 09, 2023

Showing 1-12 of 64

Last Updated: 09/26/2026